Novozymes A/S (OTCMKTS:NVZMY) Shares Gap Down - Should You Sell?

Key Points

• Novozymes shares fell 3.9%, opening at $65.29 versus the prior close of $67.43, with 5,374 shares traded.
• Analyst sentiment remains positive overall: Zacks upgraded the stock from “strong sell” to “hold,” while MarketBeat reports a consensus “Buy” rating from three analysts.
• The company’s latest results were mixed, with quarterly revenue of $1.30 billion exceeding estimates but EPS of $0.44 falling short of the $0.60 consensus forecast.

Shares of Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) gapped down prior to trading on Friday. The stock had previously closed at $67.43, but opened at $65.29. Novozymes A/S shares last traded at $65.39, with a volume of 5,374 shares traded.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Novozymes A/S from a "strong sell" rating to a "hold" rating in a research note on Monday, June 8th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy".

Novozymes A/S Trading Down 3.9%

The company has a 50 day simple moving average of $66.63 and a two-hundred day simple moving average of $62.05. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.03 and a current ratio of 1.74. The firm has a market cap of $26.87 billion, a PE ratio of 41.03, a P/E/G ratio of 2.93 and a beta of 0.93.

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) last released its earnings results on Thursday, August 20th. The biotechnology company reported $0.44 EPS for the quarter, missing analysts' consensus estimates of $0.60 by ($0.16). Novozymes A/S had a return on equity of 6.54% and a net margin of 14.70%.The firm had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.27 billion. Analysts expect that Novozymes A/S will post 2.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Novozymes A/S stock. Elefante Mark B boosted its holdings in shares of Novozymes A/S (OTCMKTS:NVZMY - Free Report) by 73.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,900 shares of the biotechnology company's stock after purchasing an additional 2,500 shares during the period. Elefante Mark B's holdings in Novozymes A/S were worth $371,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 0.03% of the company's stock.

About Novozymes A/S

Novozymes A/S was a Danish biotechnology company that developed and commercialized enzymes, microorganisms and other biological solutions for industrial and consumer applications. Its technologies were designed to help customers improve production efficiency, reduce resource use and develop more sustainable products and processes.

The company supplied biological products and related solutions to a range of industries, including food and beverages, household care, agriculture, animal health, bioenergy and industrial manufacturing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.